Science News
Discover the news and inspiring materials from the world of biotechnology.
Mabion named finalist in four categories at the Life Science Sales & Marketing Awards 2025
Mabion’s marketing and scientific excellence earned four finalist spots at the Life Science Sales and Marketing Awards 2025. We’re proud to announce Mabion’s selection as a finalist. The “Unlocking the Future of Therapeutics” contest leads the way in Campaign of the Year. Individual honours go to Paulina Toboła for Support Professional of the Year. In addition, Jakub Knurek is also shortlisted for Marketing Professional of the Year and the One to Watch Award.
Learn more
Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project
Mabion announced today that WPD Pharmaceuticals has been selected by the expert jury as the winner of its “Unlocking the Future of Therapeutics” innovation contest. WPD Pharmaceuticals will receive up to €500,000 in service credits for Mabion’s biologics development and manufacturing services with which it can accelerate the development of the next-generation antibody-drug conjugate (ADC) program in oncology.
Learn more
They understood how the immune system is kept in check: The 2025 Nobel prize in physiology or medicine
This year’s Nobel prize in physiology or medicine was awarded to researchers who discovered regulatory T cells (Tregs), whose role is to suppress the excessive immune response. Their discovery paves the way for innovative therapies, including antibody-drug conjugates that modulate the activity of immune system to fight cancer.
Learn more
Mabion is a Biologics CDMO Leadership Award Europe Finalist
Mabion has been honored as a 2025 CDMO Leadership Awards Europe winner in the Biologics category, marking a significant recognition of our scientific and operational excellence. This year’s edition of the awards represents the first European celebration of CDMO achievement, hosted at CPHI Frankfurt.
Learn more
Jakub Knurek became a finalist of the CPHI Pharma Awards in the Future Leader category
Jakub Knurek, a Marketing Specialist at Mabion S.A., has been named a finalist in the Future Leader category of the CPHI Pharma Awards 2025, to be awarded at CPHI Frankfurt on 28 October. The award recognizes rising talents in pharma, biopharma, academia, or research settings, with at least five years of relevant experience and a maximum age of 35 by the ceremony date.
Learn more
Mabion Participates in Groundbreaking Clinical Trial of Self-Regulating Immunotherapy
The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR) technology has been approved for evaluation in the clinic by the UK’s Medicine and Healthcare Products Regulatory Agency (MHRA).
Learn more
FDA Grants First Ever Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilar
For the first time in history, the FDA has granted an exemption from the requirement to conduct Clinical Efficacy Studies of biosimilar drugs containing monoclonal antibodies, signaling a fundamental shift toward evidence-based approval pathways. This exemption underscores the growing confidence in a regulatory approach based on high quality scientific research, recognizing that robust comparative data can sufficiently demonstrate biosimilarity. The removal of the requirement for Clinical Efficacy Studies represents a historic milestone for the biopharmaceutical sector, reducing the duplication of clinical knowledge already established for reference products.
Learn more
Biologics CDMO Market – Mabion Approach to Establishing Cooperation
The CDMO industry for biologics continues to grow, offering complex solutions for the biopharmaceutical industry. Mabion’s winning formula? You will find the answer in a conversation between Nigel Stapleton and Marty Henehan.
Learn more